Baseline clinical characteristics of patients according to treatment strategy
| Watchful observation group (n=186) | Early AVR group (n=98) | p Value | |
|---|---|---|---|
| Age, years | 68±11 | 68±9 | 0.66 |
| Female gender, n (%) | 103 (55) | 45 (46) | 0.13 |
| Body surface area, m2 | 1.65±0.17 | 1.64±0.12 | 0.27 |
| Symptoms | |||
| Dyspnoea, n (%) | 0.63 | ||
| NYHA I | 30 (16) | 18 (18) | |
| NYHA II | 156 (84) | 80 (82) | |
| Angina, n (%) | 52 (28) | 35 (36) | 0.18 |
| Diabetes, n (%) | 43 (23) | 24 (24) | 0.80 |
| Hyperlipidaemia, n (%) | 47 (25) | 16 (16) | 0.09 |
| Hypertension, n (%) | 127 (68) | 58 (59) | 0.13 |
| Atrial fibrillation, n (%) | 27 (15) | 16 (16) | 0.69 |
| Obstructive pulmonary disease, n (%) | 11 (6) | 7 (7) | 0.69 |
| Renal failure, n (%) | 9 (5) | 5 (5) | 1.00 |
| Coronary artery disease, n (%) | 61 (33) | 37 (38) | 0.40 |
| Creatinine, mg/dL | 1.04±0.63 | 0.99±0.58 | 0.47 |
| Comorbidity index | 1.98±1.68 | 2.11±1.55 | 0.53 |
| STS score, % | 3.11±2.97 | 3.08±2.55 | 0.92 |
AVR, aortic valve replacement; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons.